Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2007-04-10
2007-04-10
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S112000, C546S192000, C546S229000, C546S233000, C546S234000, C546S236000, C546S237000, C548S566000, C548S570000, C548S571000, C548S575000, C514S213010, C514S299000, C514S331000, C514S428000, C540S582000, C540S585000
Reissue Patent
active
11022427
ABSTRACT:
Compounds of this formulaare useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.
REFERENCES:
patent: 3234090 (1966-02-01), Huebner et al.
patent: 3274213 (1966-09-01), Lednicer
patent: 3274216 (1966-09-01), Goldsmith et al.
patent: 3277106 (1966-10-01), Bencze et al.
patent: 3293263 (1966-12-01), Lednicer
patent: 3483293 (1969-12-01), Duncan et al.
patent: 3567737 (1971-03-01), Lednicer
patent: 3862232 (1975-01-01), Lednicer
patent: 3875242 (1975-04-01), Lednicer
patent: 4133814 (1979-01-01), Jones
patent: 4358593 (1982-11-01), Jones
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 5470854 (1995-11-01), Angerer et al.
patent: 5472962 (1995-12-01), Koizumi et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5484798 (1996-01-01), Bryant et al.
patent: 5510357 (1996-04-01), Palkowitz
patent: 5532382 (1996-07-01), Carlson et al.
patent: 5552412 (1996-09-01), Cameron et al.
patent: 5567828 (1996-10-01), Dodge
patent: 6153622 (2000-11-01), Cameron et al.
patent: 6204286 (2001-03-01), Cameron et al.
patent: 6441193 (2002-08-01), Cameron et al.
patent: 0605193 (1994-07-01), None
patent: 0617030 (1994-09-01), None
patent: WO9510513 (1995-04-01), None
patent: WO9621656 (1996-07-01), None
Bencze, W.L.,J. Med. Chem., “Synthetic Estrogens, Implantation Inhibitors, and Hypocholesterolemic Agents. I. Tetrahydronaphthalene Series”, vol. 10, pp. 138-144 (1967).
Lednicer, et al.,J. Med. Chem., “Mammalian Antifertility Agents. IV. Basic 3,4-Dihydronaphthalenes and 1,2,3,4-Tetrahydro-1-naphthols”, vol. 10, pp. 78-84 (1967).
Lednicer, et al.,J. Med. Chem., “Mammalian Antifertility Agents. IV. A Novel Sequence for the Preparation of 1, 2-Disubstituted 3,4-Dihydronaphthalenes”, vol. 12, pp. 881-885 (1969).
Jones, RobertActa Endocrinologica, “The Effect of a Luteinizing Hormone-Releasing Hormone Antagonist on Experimental Endometriosis in the Rat”, vol. 114, pp. 379-382 (1967).
Jones, Charles D.,J. Med. Chem.J. Med. Chem., “Anitestrogens. 2. Structure-Activity Studies in a Series of 3-Aroyi-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(piperidinyl)ethoxl]-phenyl]methadone Hydrochloride (LY 156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity”, vol. 27, pp. 1057-1066 (1984).
Nagarajan, K.,Indian Journal of Chemistry, “Antimplantation Agents: Part II—1,2-Diaryl-1,2,3,4-tetrahydroisoquinolines”, vol. 24B, pp. 83-97 (1985).
Osteoporosis Conference, SCRIP No. 1812/13 Apr. 16th/20th, 1993, pp. 29-30.
Tzukerman, M.T.,Molecular Endocrinology, “Human Estrogen Receptor Transactivational Capacity is Determined by both Cellular and Promoter Context and Mediated by Two Functionally Distinct Intramolecular Regions”, vol. 8, pp. 21-30 (1994).
Chemical Abstracts, vol. 64, pp.15811-15814, 1966.
Chemical Abstracts, vol. 66, Abstract 46256d, 1967.
Chemical Abstracts, vol. 73, Abstract 76943n, 1970.
The Merck Manual. “Bone and Cartilage Disorders with Articular Manifestations”, 18thEdition, pp. 1357-1359 (1992).
Hutchens, et al.,Molecular Endocrinology, “Unique Molecular Properties of a Urea- and Salt-Stable DNA-Binding Estrogen Receptor Dimmer Covalently Labeled With The Antiestrogen [3H] Desmethylnafoxidine Aziridine.”, pp. 255-267, (1990).
Katzenellenbogen, et al.,Hormones and Cancer, “Antiestrogen Action in Estrogen Target Tissues: Receptor Interactions And Antiestrogen Metabolism”, pp. 309-320, (1980).
Katzenellenbogen, et al.,Journal of Steroid Biochemistry, “Antiestrogen Pharmacology and Mechanism of Action”, vol. 19, pp. 59-68, (1983).
Leclercq, et al.,Journal of Steroid Biochemistry, “Guide-Lines in The Design Of New Antiestrogens And Cytotoxic-Linked Estrogens For The Treatment Of Breast Cancer”, vol. 19, pp. 75-85, (1983).
Tatee, et al.,Journal of Medicinal Chemistry, “Antiestrogens and Antiestrogen Metabolites: Preparation of Tritium-Labeled (±)-cis-3-[p-(1,2,3,4-Tetrahydro-6-methoxy-2-phenyl-1-naphthyl) phenoxy]-1,2-propanediol (U-23469) and Characterization and Sythesis of a Biologically Important Metabolite”, vol. 22, pp. 1509-1517, (1979).
Chemical Abstracts, vol. 65, No. 3., Abstract 5425b, Aug. 1, 1996.
Lednicer, Daniel, et al., J. Med. Chem. 10 78 (1967) “Mammalian Antifertility Agens. IV. Basic 3,4-Dihydronaphthalenes and 1,2,3,4-Tetrahydro-1-naphthols”.
Bencze, W. L., et al., J. Med. Chem. 10 139 (1967) “Synthetic Estrogens, Implantation Inhibitors, and Hypocholesterolemic Agents. I. Tetrahydronaphthalene Series”.
Lednicer, Daniel, et al., J. Med. Chem. 12 881 (1969) “Mammalian Antifertility Agents. VII. A Novel Sequence for the Preparation of 1,2-Disubstituted 3,4-Dihydronaphthalenes”.
Jones, Robert C., Acta Endocrinologica (Copenh) 1987, 114:379-382 “The Effect of a Luteinizing Hormone-Releasing Hormone Antagonist on Experimental Endometriosis in the Rat”.
Osteoporosis Conference, CRIP No. 1812/13 Apr. 16th/20th 1993. pp. 29-30.
Jones, Charles D., et al., J. Med. Chem. (1984) 27, 1057-1066 “Antiestrogens. 2. Structure -Activitiy Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity”.
Cameron Kimberly O.
DaSilva Jardine Paul A.
Rosati Robert L.
Benson Gregg C.
Davis Zinna N.
Pfizer Inc.
Wichtowski John A.
LandOfFree
5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3781972